Premium
Polo‐like kinase‐1 immunoreactivity is associated with metastases in cutaneous melanoma
Author(s) -
Kaczorowski Maciej,
Borowiec Tomasz,
Donizy Piotr,
Pagacz Konrad,
Fendler Wojciech,
Lipinski Artur,
Halon Agnieszka,
Matkowski Rafal
Publication year - 2017
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.12985
Subject(s) - pathology , medicine , melanoma , immunohistochemistry , anatomical pathology , cancer research
Background Polo‐like kinase‐1 ( PLK ‐1) is one of the key regulators of cell cycle progression. Increased expression of PLK ‐1 was observed in several tumor types. Methods We immunohistochemically assessed PLK ‐1 expression in neoplastic and stromal compartments of 96 cutaneous melanomas, and analyzed associations between PLK ‐1 expression and clinicopathological characteristics. Results PLK ‐1 expression in cancer cells was not associated with basic clinical (eg, age, gender and tumor location) or histopathological (eg, Breslow thickness, mitotic rate and ulceration) parameters. However, increased PLK ‐1 was more frequent in tumors with concurrent regional nodal metastases and positive sentinel lymph node biopsy status. All primary tumors associated with co‐existing distant metastases exhibited high PLK ‐1 expression in melanoma cells. Conversely, PLK ‐1 expression in stromal cells was more frequent in tumors without nodal metastases. PLK ‐1 expression in both compartments was not associated with survival. Conclusion PLK ‐1 expression is associated with metastatic potential in cutaneous melanoma.